Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma

Model scores of the 29,894 trials active now.

Model score 35% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-03-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: and neckhead andradiationbowelheart
  Phrases that lowered it: metastaticprogressionthe efficacysunitinibevaluate the
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 60 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 97.8% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 25.8% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 60 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 2663 (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma NCT01371201 · started 2011 · scored riskier than 99% of active trials completed
• Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies NCT01243359 · started 2010 · scored riskier than 26% of active trials completed
• Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease NCT01168440 · started 2010 · scored riskier than 96% of active trials completed
• Sequential Study to Treat Renal Cell Carcinoma NCT00732914 · started 2009 · scored riskier than 64% of active trials completed
• Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. NCT03066427 · started 2017 · scored riskier than 80% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.